Printer Friendly

MEDICIS PHARMACEUTICAL ANNOUNCES REDEMPTION OF CLASS A WARRANTS

    MEDICIS PHARMACEUTICAL ANNOUNCES REDEMPTION OF CLASS A WARRANTS
    NEW YORK, Jan. 7 /PRNewswire/ -- Medicis Pharmaceutical Corporation (NASDAQ: MDRXA) announced today that it had called for redemption on Feb. 10, 1992, all of its outstanding redeemable Class A warrants, at a price of $.05 per warrant.
    Each Class A warrant is exercisable prior to 5 p.m., New York City time, on Monday, Feb. 10, 1992, for one share of Class A common stock and one Class B warrant at an exercise price of $1.50.
   On Jan. 6, 1992, the closing bid price per share of Class A common stock, as reported on the National Association of Securities Dealers Automated Quotations System, was $2-7/16.
    For further information, contact Stuart Diamond, senior vice president, chief financial officer and secretary of Medicis Pharmaceutical, 212-599-2000, or Vincent Coakley of D.H. Blair & Co., the company's solicitation agent, 212-495-4100.
    -0-               1/7/92
    /CONTACT:  Stuart Diamond of Medicis Pharmaceutical, 212-599-2000/
    (MDRXA) CO:  Medicis Pharmaceutical Corporation ST:  New York IN:  MTC SU: PS -- NY079 -- 7503 01/07/92 17:27 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1992
Words:177
Previous Article:AMEX MARKET VALUE INDEX REACHES NEW ALL-TIME RECORD HIGH AMERICAN STOCK EXCHANGE DAILY REPORT
Next Article:THE TORONTO STOCK EXCHANGE MARKET CLOSING
Topics:


Related Articles
CYTRX ANNOUNCES EXERCISE OF CLASS B WARRANTS
LIDAK PHARMACEUTICALS ESTIMATES $8.4 MILLION RAISED FROM EXERCISE OF WARRANTS
LIDAK PHARMACEUTICALS SIGNS AGREEMENT IN PRINCIPLE FOR U.S. LICENSING AGREEMENT AND EXTENDS CLASS A WARRANT REDEMPTION DEADLINE
ALPHA 1 BIOMEDICALS, INC. COMPLETES
MEDICIS PHARMACEUTICAL TO PROPOSE REVERSE STOCK SPLIT
MEDICIS PHARMACEUTICAL ANNOUNCES 1 FOR 14 REVERSE STOCK SPLIT
MEDICIS PHARMACEUTICAL ANNOUNCES SHAREHOLDER APPROVAL OF A 1 FOR 14 REVERSE STOCK SPLIT
MEDICIS PHARMACEUTICAL CORPORATION ANNOUNCES AMENDMENT OF RIGHTS PLAN
MEDICIS ANNOUNCES A 3 FOR 2 STOCK SPLIT EFFECTED IN THE FORM OF A 50% STOCK DIVIDEND
Medicis Announces a 3 for 2 Stock Split Effected in the Form of a 50% Stock Dividend

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters